1.1 Research Scope: Depicting the Future of Therapy

1.2 Research Framework: Value of Innovation

1.3 Research Methodology: The Core Value

1.4 Key Facts and Findings: Patents as the Vital Component

1.5 Key Elements of Analysis: Finding the Best Approach

2.1 Technology Segmentation: The Four Therapies

2.2 Key Innovations: Perfect Scenario for Tech Synergy

2.3 Key Approaches: CAR-T Cell Calling Most Attention

3.1 Innovation Ecosystem: Focus on Public/Private Cooperation

3.2 Breadth of Industries: The Road Beyond Therapeutics

3.3 Global Responsibility Environment: Building Values

3.4 Technology/Business Accelerators: Stem Cells Are Attracting Maximum Attention

3.5 Technology/Business Challenges: There is the Need for Setting Common Standards

3.6 Technology/Business Trends: Prevalence of Strategic Advisory Bodies

4.1 Regenerative Medicine Value Chain: Strong Public and Private Investment

4.2 Repercussions in Business and Processes: New Business Models and Manufacturing Strategies

4.3 Emerging Business Models in Regenerative Medicine: The Six Pathways to Follow

4.4 Value Chain Interactive Model: The Six Key Elements of Interaction

4.5 Supply Chain Management: From Cell Collection to Therapy Administration and Surveillance

4.6 Manufacturing Workflow for Allogeneic Products: Scale-up-based, On-demand Production

4.7 Manufacturing Workflow for Autologous Products: Patient-centered, Clinic-specific Production

4.8 Manufacturing Workflow for Decellularized Products: Off-the-shell Production

4.9 Manufacturing Workflow for 3D Bioprinted Products: Between Off-the-shell and Customized Production

5.1 New Initiatives: The Japan’s Post Market Surveillance Strategy

5.2 Legal Framework: Safety and Promotion Act for Regenerative Medicine

5.3 Product Development and Commercialization: Conditional Approval Strategy

5.4 Time to Market: Conventional Product Cycle Time

5.5 Time to Market: Post Market Surveillance Cycle Time

5.6 Industry Interaction Strategy: The Case of Japan

5.7 Industry Interaction Strategy: Key Players across Industries in Japan

5.8 Key Global Strategic Agreements: uniQure N.V. and Bristol-Myers Squibb in Billionaire Collaboration

5.9 Key Initial Public Offerings: Spark Therapeutics Raises $185.2 Million in IPO

6.1 Key Positions: Customer Niches and Biovalue Creation

6.2 Pipeline Regional Distribution: North America is the Largest Developer

6.3 Pipeline Therapeutic Distribution: The Diverse World of Applications and Commercialization Opportunities

6.4 Regenerative Medicine Pipeline: Celyad to Complete Phase III for Congestive Heart Failure

6.5 Regenerative Medicine Pipeline: Mesoblast to Launch MLCs for Rheumatoid Arthritis

6.6 Regenerative Medicine Pipeline: uniQure to Launch in Vivo Gene Therapy for Hemophilia B

7.1 Market Potential: The Global Regenerative Medicine Market to Rise at a CAGR of 22.4% from 2015–2025

7.2 Market Segmentation: Immune Cellular Therapy at the Front

7.3 Funding and Investment Trends: Operations Duplicated in the past Two Years

7.4 Market Impact and Opportunities: Massive Investment in World Class-accredited Manufacturing Facilities

7.5 Targeted Therapeutic Areas: Tissue Engineering One of the Main Target Areas

7.6 Global Footprint: North America Advances Industry Development

7.7 Intellectual Property Landscape

7.8 Patent Publishing Trends

7.9 Top Assignees

7.10 Top International Patent Offices

7.11 Key Questions for Success

8.1 The Road Ahead: Innovation Model Driving Regenerative Medicine

8.2 The Road Ahead: Open Collaboration Models to Lead Developments in Selected Areas

8.3 The Road Ahead: Increasingly Intelligent Manufacturing Processes in the Value Chain

8.4 Mergers and Acquisitions Model: The Case of Fujifilm Corporation

8.5 Science Driven Model: The Case of Osiris Therapeutics

8.6 IP and Manufacturing Model: The Case of Pluristem Therapeutics

8.7 Clinical and Financial De-risking Model : The Case of BioTime

9.1 Multicriteria Approach for Benchmarking

9.2 Multicriteria Approach for Benchmarking: Strategic Portfolio Management

9.3 Multicriteria Approach for Benchmarking: Level 0 Criteria

9.4 Multicriteria Approach for Benchmarking Level 1 Criteria: Research and Development

9.5 Multicriteria Approach for Benchmarking Level 1 Criteria: Financial Support and Funding

9.6 Multicriteria Approach for Benchmarking Level 1 Criteria: Market Landscape

9.7 Multicriteria Approach for Benchmarking: Level 2 Criteria

9.8 Multicriteria Approach Analytic Results

9.9 Multicriteria Approach Final Remarks

9.10 Assessment of Strategies

9.11 Assessment of Strategic Cases

9.12 Final Remarks

10.1 Key Companies in North America

10.1 Key Companies in North America (continued)

10.1 Key Companies in North America (continued)

10.1 Key Companies in North America (continued)

10.1 Key Companies in North America (continued)

10. 1 Key Companies in North America (continued)

10. 1 Key Companies in North America (continued)

10. 1 Key Companies in North America (continued)

10. 1 Key Companies in North America (continued)

10.1 Key Companies in North America (continued)

10.1 Key Companies in North America (continued)

10.1 Key Companies in North America (continued)

10.1 Key Companies in North America (continued)

10.1 Key Companies in North America (continued)

10.1 Key Companies in North America (continued)

10.1 Key Companies in North America (continued)

10.1 Key Companies in North America (continued)

10.1 Key Companies in North America (continued)

10.1 Key Companies in North America (continued)

10.1 Key Companies in North America (continued)

10.1 Key Companies in North America (continued)

10.2 Key Companies in Europe

10.2 Key Companies in Europe (continued)

10.2 Key Companies in Europe (continued)

10.2 Key Companies in Europe (continued)

10.2 Key Companies in Europe (continued)

10.2 Key Companies in Europe (continued)

10.2 Key Companies in Europe (continued)

10.2 Key Companies in Europe (continued)

10.2 Key Companies in Europe (continued)

10.3 Key Companies in Asia-Pacific

10.3 Key Companies in Asia-Pacific (continued)

10.3 Key Companies in Asia-Pacific (continued)

10.4 Key Industry Influencers

10.4 Key Industry Influencers (continued)

10.4 Key Industry Influencers (continued)

10.4 Key Industry Influencers (continued)

10.5 Key Granted Patents

10.5 Key Granted Patents (continued)

10.5 Key Granted Patents (continued)

Legal Disclaimer

11.1 The Frost & Sullivan Story

11.2 Value Proposition: Future of Your Company & Career

11.3 Global Perspective

11.4 Industry Convergence

11.5 360º Research Perspective

11.6 Implementation Excellence

11.7 Our Blue Ocean Strategy